Acute kidney injury due to gentamicin nephrotoxicity and specific miRNAs as biomarkers
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F25%3AE0111529" target="_blank" >RIV/00843989:_____/25:E0111529 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/61988987:17110/25:A2603AIJ RIV/61989592:15110/25:73628137 RIV/00098892:_____/25:10158842
Výsledek na webu
<a href="https://biomed.papers.upol.cz/artkey/bio-202501-0001_acute-kidney-injury-due-to-gentamicin-nephrotoxicity-and-specific-mirnas-as-biomarkers.php" target="_blank" >https://biomed.papers.upol.cz/artkey/bio-202501-0001_acute-kidney-injury-due-to-gentamicin-nephrotoxicity-and-specific-mirnas-as-biomarkers.php</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.5507/bp.2024.031" target="_blank" >10.5507/bp.2024.031</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Acute kidney injury due to gentamicin nephrotoxicity and specific miRNAs as biomarkers
Popis výsledku v původním jazyce
Acute kidney injury (AKI) due to gentamicin nephrotoxicity is a significant concern in clinical medicine, particularly in patients receiving prolonged or high-dose gentamicin therapy. Gentamicin is an aminoglycoside antibiotic frequently used in the treatment of a range of bacterial infections. However, its use is associated with nephrotoxicity which can manifest as AKI. Due to this, it is crucial to diagnose promptly and manage treatment effectively. Ongoing studies are therefore focusing on non-protein-coding RNAs as potential biomarkers for AKI. Numerous microRNAs (miRNAs) have been implicated in gentamicin-induced nephrotoxicity and AKI. They participate in pathways associated with inflammation, cell death, and oxidative stress and each of these factors play critical roles in the development of gentamicin-induced kidney injury. Research studies have demonstrated changes in the expression levels of these miRNAs in response to gentamicin exposure both in vitro and in in vivo models, as well as in human clinical trials involving patients receiving gentamicin therapy. The dysregulation of these miRNAs correlates with the severity of kidney injury and may serve as sensitive biomarkers for early detection and monitoring of AKI induced by gentamicin.
Název v anglickém jazyce
Acute kidney injury due to gentamicin nephrotoxicity and specific miRNAs as biomarkers
Popis výsledku anglicky
Acute kidney injury (AKI) due to gentamicin nephrotoxicity is a significant concern in clinical medicine, particularly in patients receiving prolonged or high-dose gentamicin therapy. Gentamicin is an aminoglycoside antibiotic frequently used in the treatment of a range of bacterial infections. However, its use is associated with nephrotoxicity which can manifest as AKI. Due to this, it is crucial to diagnose promptly and manage treatment effectively. Ongoing studies are therefore focusing on non-protein-coding RNAs as potential biomarkers for AKI. Numerous microRNAs (miRNAs) have been implicated in gentamicin-induced nephrotoxicity and AKI. They participate in pathways associated with inflammation, cell death, and oxidative stress and each of these factors play critical roles in the development of gentamicin-induced kidney injury. Research studies have demonstrated changes in the expression levels of these miRNAs in response to gentamicin exposure both in vitro and in in vivo models, as well as in human clinical trials involving patients receiving gentamicin therapy. The dysregulation of these miRNAs correlates with the severity of kidney injury and may serve as sensitive biomarkers for early detection and monitoring of AKI induced by gentamicin.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30217 - Urology and nephrology
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2025
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Biomedical papers
ISSN
1213-8118
e-ISSN
1804-7521
Svazek periodika
169
Číslo periodika v rámci svazku
1
Stát vydavatele periodika
CZ - Česká republika
Počet stran výsledku
8
Strana od-do
1-8
Kód UT WoS článku
001334882700001
EID výsledku v databázi Scopus
2-s2.0-86000714883